ClinicalTrials.gg

Program

BCD-261

A development code. Also written as “BCD-261, pre-specified therapeautic dose X”, “BCD-261, dose 1” and “BCD-261, dose 2”.

Its studies are mostly in Colitis, Ulcerative, led by 2 companies.

Furthest: phase 1, since Nov 28, 20242 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocad11 open or runningphase 1since Nov 28, 2024Nov 28, 2024none ahead
SPH-BIOCAD (HK)11 open or runningphase 1since Mar 31, 2026Mar 31, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2024First study: phase 1 study in Colitis, UlcerativeNew to BiocadBiocad · NCT06715540 · 48 planned · Russian Federation
  2. Mar 31, 2026SPH-BIOCAD (HK)’s first study: phase 1 study in Healthy Adult ParticipantsNew to SPH-BIOCAD (HK)SPH-BIOCAD (HK) · NCT07535775 · 48 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07535775Healthy Adult Participants · China1Active, not recruitingSPH-BIOCAD (HK)Oct 10, 202648
NCT06715540Colitis, Ulcerative · Russian Federation1RecruitingBiocadFeb 202548

How it is read

Names in the registry

  • “BCD-261, pre-specified therapeautic dose X”, 2 entries
  • “BCD-261”, 1 entry
  • “BCD-261, dose 1”, 1 entry
  • “BCD-261, dose 2”, 1 entry
  • “BCD-261, dose 3”, 1 entry

Codes read as this program: BCD261.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.